NEW YORK (GenomeWeb News) – Pressure BioSciences has filed with US regulators for a direct offering of a maximum of $5 million of its Series F preferred stock.

In an amended preliminary prospectus filed with the US Securities and Exchange Commission on Friday, Pressure Bio said it plans to offer 5,000 shares of its Series F preferred stock at $1,000 per share. The stock is being offered directly to one or more accredited investors.

Moody Capital Solutions is acting as placement agent on the offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcripts, and more.

While James Watson and Francis Crick are credited for discovering the structure of DNA, Rich proved their theory of a double helix structure was correct when he produced a distinct image of the structure.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

According to MIT Technology Review, Apple is collaborating with researchers to develop apps for consumer DNA testing.